{
    "clinical_study": {
        "@rank": "58537", 
        "acronym": "GASWI", 
        "arm_group": [
            {
                "arm_group_label": "Copaxone MRI", 
                "description": "Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI."
            }, 
            {
                "arm_group_label": "Healthy Controls MRI", 
                "description": "Subjects who are otherwise healthy, without neurological disorders, will have a MRI."
            }
        ], 
        "brief_summary": {
            "textblock": "To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in\n      subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over\n      24 months and compared to a reference population of healthy controls."
        }, 
        "brief_title": "A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, observational, single-blinded, longitudinal, 24-month MRI study of\n      the evolution of iron deposits, as evidenced by SWI-filtered phase imaging, in RRMS patients\n      treated with GA and in healthy controls."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  MS patients diagnosed with clinically definite MS according to the McDonald criteria\n             (Polman et al., 2005)\n\n          -  Being on GA monotherapy (20mg/day sc) for at least 24 months prior to the 24-month\n             MRI scan\n\n          -  Having baseline clinical MRI scan that included SWI-filtered phase imaging in a\n             12-month window from the start day of the of the GA (MS patients)\n\n          -  Having baseline clinical MRI scan that included SWI-filtered phase imaging (healthy\n             controls)\n\n          -  MS patients having a RR disease course (Lublin and Reingold, 1996)\n\n          -  Age 18-65 (healthy controls will be matched to MS patients for age and sex)\n\n          -  Signed informed consent at the 24-month follow-up\n\n          -  Pass MRI health screening\n\n          -  MS patients passing contrast screening\n\n          -  MS patients having normal kidney function (creatinine clearance >59)\n\n          -  None of the exclusion criteria\n\n        Exclusion Criteria:\n\n          -  Patients who had a relapse within 30 days prior to MRI baseline scan date\n\n          -  Patients who received steroid treatment within 30 days prior to the MRI baseline scan\n             date\n\n          -  Women who are pregnant, lactating or of childbearing age who do not consent to\n             approved contraceptive use during the study\n\n          -  MS patients who used other imunomodulatory or immunosuppressant treatment other than\n             GA during the follow-up (e.g., IFN-\u03b2, mitoxantrone, cyclophosphamide, cladribine,\n             fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept,\n             natalizumab, etc.)\n\n          -  MS patients having abnormal kidney function (creatinine clearance <59)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "MS patients from the Baird MS Center, The Jacobs Neurological Institute, Department of\n        Neurology, State University at Buffalo, NY, USA who are also taking Copaxone as their\n        disease modifying therapy.\n\n        Healthy controls from the general population."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695434", 
            "org_study_id": "GA-SWI 24"
        }, 
        "intervention": {
            "arm_group_label": [
                "Copaxone MRI", 
                "Healthy Controls MRI"
            ], 
            "description": "All subjects will undergo a MRI.", 
            "intervention_name": "MRI", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Copolymer 1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "multiple sclerosis", 
            "MRI", 
            "Copaxone", 
            "healthy controls", 
            "glatiramer acetate"
        ], 
        "lastchanged_date": "March 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14203"
                }, 
                "name": "Buffalo Neuroimaging Analysis Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: HSIRB", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "MRI collected from RRMS patients who have taken Copaxone for 24 months", 
            "measure": "To explore whether treatment with GA may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695434"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University at Buffalo", 
            "investigator_full_name": "Robert Zivadinov, MD, PhD", 
            "investigator_title": "Director, Buffalo Neuroimaging Analysis Center, Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Evaluate if Copaxone will decrease iron in lesions.", 
            "measure": "To investigate whether treatment with GA may decrease accumulation of iron in lesions, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months.", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "University at Buffalo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University at Buffalo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}